Skip to content
Back to search results

Impact of Vision Impairment Scale

Introduced by
Wolffsohn JS, Cochrane AL et al.
Year
2000
Type
Self-report
Family
low vision quality of life
Font size

What does it do?

The Impact of Vision Impairment (IVI) scale is a quality-of-life instrument designed specifically for patients with significant vision loss (low vision) to measure the psychological, functional, and social burden of visual impairment.

Developed by Wolffsohn, Cochrane, and colleagues (2000), the IVI captures domains including emotional impact (distress, frustration), functional limitations (mobility, ADLs), social participation, and role fulfillment in populations with moderate to severe vision loss where generic or mild-vision-focused instruments are insensitive.

The intuition behind the method

Vision loss of sufficient severity to qualify as 'low vision' (best corrected acuity <20/60 or visual field <20°) represents a profound life transition. Beyond functional disability (difficulty reading, mobility), patients experience grief, identity loss, social withdrawal, and altered life roles. Family dynamics shift, economic participation may cease, and psychological burden can exceed physical disability. Generic vision instruments (VFQ-25, OSDI) may show floor effects or miss the existential and psychosocial impact central to low vision rehabilitation. The IVI directly addresses emotional, social, and participatory dimensions alongside functional loss, acknowledging that low vision is not just about acuity but about coping, adaptation, and meaningful participation.

History

Developed by Wolffsohn, Cochrane, and colleagues at Aston University, UK (2000), as an adaptation and expansion of earlier low vision QoL work. Published in Optometry & Vision Science. Emerged from recognition that existing generic vision measures (VFQ-51/VFQ-25) were insensitive in the severe vision loss range and missed emotional and social domains critical to low vision rehabilitation. Refined versions (e.g., LVQOL Extended) developed thereafter. Adopted internationally in low vision clinics and rehabilitation programs, particularly in Europe and Oceania. FDA and national guidelines for low vision care recognize IVI or related multidimensional measures as appropriate outcome tools.

When to use it

Appropriate for any patient with low vision (acuity <20/60 Snellen or visual field <20°) from any cause (macular degeneration, retinitis pigmentosa, optic neuropathy, advanced glaucoma, severe diabetic retinopathy, corneal scarring, etc.). Baseline assessment at low vision rehabilitation intake documents starting burden. Repeat at 4–6 week, 3-month, and 6-month intervals to track emotional, functional, and social progress through rehabilitation. Particularly valuable when patient's disability and distress seem disproportionate to objective acuity, suggesting significant psychosocial component warranting counseling or group support.

Limitations and considerations

  • Requires substantial vision or adaptations to administer: self-report reading small text difficult in low vision; telephone or large-print/audio administration needed, increasing burden
  • Variability in versions and scoring: multiple IVI/LVQOL variants exist with different item counts, subscale structures, and conversion formulas—not all published papers use identical instruments
  • Limited cross-cultural validation: less extensively translated and validated globally compared to VFQ-25; norms vary by region and healthcare system
  • Does not capture adaptive resilience or positive aspects: measures burden and limitation but not growth, acceptance, or meaningful adaptation some low vision patients achieve
  • Heterogeneous low vision populations: AMD patients (usually older, slower onset) have different QoL trajectories than young retinitis pigmentosa patients (young, progressive, genetic); single IVI score may obscure these differences

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Low vision-specific: designed for and validated in populations with moderate-to-severe vision loss, where generic vision scales show floor effects or miss key domains
  • Multidimensional: captures functional, emotional, social, and role dimensions of low vision impact, not just activity limitation but existential and psychological burden
  • Responsive to rehabilitation: documents meaningful improvements in emotional well-being, independence, and social participation after adaptive training and aids
  • Addresses often-neglected domains: explicitly measures grief, frustration, social withdrawal, and identity concerns central to low vision experience but absent from activity-based instruments
  • Validated in diverse low vision populations: tested across multiple etiologies (AMD, RP, optic neuropathy, etc.) and ages, with good reliability and responsiveness

How it works

How it works

1

The original IVI comprises multiple items (often 30–40 items in extended versions) covering functional, emotional, social, and role limitation domains. Items are rated on Likert scales (1–5 or 0–4) reflecting frequency or agreement with statements (e.g., 'I feel frustrated because of my vision loss', 'I have difficulty doing fine detail work', 'I avoid social situations'). Extended IVI or LVQOL (Low Vision Quality of Life) variants exist with slightly different item counts and structures. Administration is 10–15 minutes depending on version. Suitable for adults (18+) with low vision diagnosis (acuity <20/60 or field <20°). Self-report or interviewer-administered (interview often preferred in low vision populations due to visual difficulty reading scales).

2

Items are summed to yield subscale scores (e.g., Reading and Accessing Information, Mobility, Social Well-being, Emotional Well-being, Independence) and often a global IVI score. Total scores or subscales are converted to 0–100 scales in many versions, with lower scores indicating greater impact (worse QoL) and higher scores indicating less impact (better QoL), or vice versa depending on scoring convention—always check the published instrument manual for the specific version used. Minimal Clinically Important Difference (MCID) typically 5–10 points depending on subscale.

3

Interpretation depends on version and subscale. Generally: scores in the lower range (0–30 on 0–100 scale) indicate high burden and poor QoL related to vision loss; scores in mid-range (31–65) indicate moderate impact; higher scores (66–100) indicate minimal impact or good coping despite vision loss. Subscale patterns reveal where patient's burden is concentrated: high Reading/Information domain score indicates severe functional limitation in literacy; high Emotional domain score indicates depression, anxiety, or grief; low Social domain score suggests withdrawal and isolation. Comparisons to low vision population norms contextualize individual severity.

4

Low vision rehabilitation outcome measurement: IVI documents functional and emotional gains from adaptive aids, skills training, orientation & mobility instruction, and psychological support Treatment prioritization: IVI identifies whether patient's burden is primarily functional (mobility aids, environmental modification priority) or emotional (counseling, peer support priority) Clinical research in retinal disease (AMD, inherited retinal dystrophies, diabetic retinopathy): secondary endpoint measuring QoL impact beyond visual acuity progression Health economic analysis: estimating burden of disease and cost-effectiveness of interventions (rehabilitation, pharmacotherapy) in low vision populations

Common pitfalls

  • Using IVI in non-low-vision populations: the instrument is designed for acuity <20/60; in mild-to-moderate vision loss (20/60–20/30), broader instruments like VFQ-25 are more appropriate and responsive
  • Assuming high IVI burden scores indicate poor prognosis or little rehabilitation benefit: substantial emotional distress at baseline often improves with counseling, peer support, and adaptive aids; rehabilitation outcome depends on engagement and motivation, not baseline scores alone
  • Conflating IVI emotional domain with clinical depression or anxiety disorder: elevated frustration/distress on IVI may reflect appropriate grief response to vision loss, not pathological mood; mental health assessment needed separately
  • Neglecting subjective vision rating items: some IVI versions include single-item ratings of overall vision quality or functional vision; these subjective ratings may diverge from acuity and should not be ignored in interpretation

Frequently asked questions

How does IVI differ from the NEI-VFQ-25 in low vision populations?

VFQ-25 is designed for broader vision loss across all severities and shows floor effects (many low-vision patients score near zero, losing discriminant power). IVI is specifically designed for low vision (acuity <20/60) and includes emotional, social, and existential domains (e.g., grief, identity, role loss) not captured in VFQ-25. In low vision rehabilitation, IVI is more responsive to change from counseling and aids. Many programs use both for comprehensive assessment.

What IVI score change indicates meaningful improvement from rehabilitation?

MCID is typically 5–10 points depending on subscale and version. Clinically, improvement of 10–20 points on a subscale over 3–6 months of rehabilitation (adaptive aids, skills training, counseling) indicates substantial benefit. Emotional domain improvements of 10+ points suggest reduced distress; Social domain improvements indicate restored participation.

Can IVI be used in completely blind patients (no light perception)?

IVI can be adapted for blindness, but many items reference vision loss rather than absence of vision; floor effects occur. In total blindness, orientation & mobility outcomes, independence in ADLs, and psychosocial measures (depression, social participation) are more interpretable than vision-specific QoL scores. Consider blindness-specific instruments (e.g., Functioning Everyday with a Visual Impairment scale) in this population.

Is IVI proprietary, and can clinicians use it freely?

IVI is not proprietary; freely available for clinical and research use. Always cite Wolffsohn & Cochrane (2000) in publications. Some extended versions or validated translations may have minor restrictions; check the published validation paper for your target version/language.

Related methods

Sources

  1. Wolffsohn, J. S., & Cochrane, A. L. (2000). Design of the low vision quality-of-life questionnaire (LVQOL) and measurment of its item and scale validity and reliability. Optometry & Vision Science, 77(3), 144-152.

    Open publication reference
    Copied.
  2. Owsley, C., McGwin, G., & Scilley, K. (2007). The VisionCare Study: design and methods. Curr Eye Res, 32(4), 325-332.

    Open publication reference
    Copied.